Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%Open in a New Window

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Commission (EC) has granted a marketing authorisation for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult

 

Healthcare at a Crossroads: What’s the Path Forward?Open in a New Window

RYE, N.Y.--(BUSINESS WIRE)--Gabelli Funds and Columbia Business School are hosting a unique healthcare symposium to provide a platform for industry and academic leaders to address critical issues facing the healthcare industry today. The panelists consist of executives from the healthcare ecosystem, including providers, payers, pharmaceutical companies, pharmacy benefit managers, wholesalers and academia. Specifically, the symposium will address the 2020 election and its implications for the he

 

STAT’s First-ever Biomedical Innovation Award Awarded to Dr. Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer CenterOpen in a New Window

BOSTON--(BUSINESS WIRE)--The award was announced on Nov. 21 at the inaugural STAT Summit, and celebrates one academic researcher.

 

Vizient and Fresenius Kabi Complete Novaplus Contract Enhancement for Six Critical Care DrugsOpen in a New Window

IRVING, Texas--(BUSINESS WIRE)--Vizient announces an agreement with Fresenius Kabi to supply six critical care drugs under its successful Novaplus private label pharmacy program.

 

Axonics® Announces Agreement to Supply its Sacral Neuromodulation System to The University of Tennessee Medical CenterOpen in a New Window

IRVINE, Calif. & KNOXVILLE, Tenn.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has entered into an agreement to supply the Axonics r-SNM® System to The University of Tennessee Medical Center (UTMC) in Knoxville, Tennessee. UTMC has been implanting SNM devi

 

Bayer and Shionogi Europe to Keynote Veeva Commercial & Medical Summit, EuropeOpen in a New Window

BARCELONA, Spain--(BUSINESS WIRE)--Shionogi Europe and Bayer are featured keynote speakers at 2019 Veeva Commercial & Medical Summit, Europe.

 

Company Profile for Immune-Onc Therapeutics, Inc.Open in a New Window

--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collab

 

Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative PatientsOpen in a New Window

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A recent study used Masimo Patient SafetyNet™ and RAM® with RRa® to help identify desaturation and bradypnea in postoperative patients.

 

NTT Com Wins Two MEF 3.0 Proof of Concept AwardsOpen in a New Window

TOKYO--(BUSINESS WIRE)--NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO: 9432), announced today it received MEF 3.0 Proof of Concept Awards in two categories, “MEF3.0 SD-WAN Implementation 2019” and “Network Slicing Implementation 2019,” during the MEF 3.0 Proof of Concept Showcase event held in the U.S. city of Los Angeles from November 18 to 22. The showcase was organized by the Metro Ethernet Forum (MEF), a glo

 

Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common StockOpen in a New Window

BOSTON, Mass.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the pricing of its previously announced underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to Karuna from the offerin

 

NIC CEO, Employees Run the Extra Mile, Raise More Than $235,000 for St. Jude Children’s Research Hospital®Open in a New Window

OLATHE, Kan.--(BUSINESS WIRE)-- #BeastModeRunners--What started as a challenge grew into a movement, impacting complete strangers in more ways than one and raising more than $235,000 for St. Jude.

 

Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-CellsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

 

Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers SquibbOpen in a New Window

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights (NASDAQ: CELGZ) (“Celgene CVRs”) that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange (“NYSE”). As a result, Celgene notified the NASDAQ Global Market today of it

 

Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma CompanyOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of Bristol-

 

Glaukos Announces Participation in Piper Jaffray Healthcare ConferenceOpen in a New Window

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 2:30 p.m. EST in New York City. A live audio webcast for this event will be available in the Investors section of the Glaukos

 

QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutionsOpen in a New Window

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutions

 

Illumina to Webcast Upcoming Investor Conference PresentationsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast. Evercore ISI HealthCONx Conference in Boston, MA Wednesday, December 4, 2019 at 8:45am Eastern Time Piper Jaffray Annual Healthcare Conference in New York, NY Thursday, December 5, 2019 at 10:30am Eastern Time The live webcasts can be accessed in the Investor Relations section of Illumina's web site

 

Carlisle Companies Completes Purchase of ProvidienOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Carlisle Companies Incorporated (NYSE:CSL) announced today that it has completed the purchase of Providien, LLC. Based in San Diego, California, Providien, LLC is a leading provider of comprehensive solutions for global medical technology OEMs, including: contract manufacturing, precision machining and metals, thermoforming and injection molding. About Carlisle Companies Incorporated Carlisle Companies Incorporated is a diversified, global portfolio of niche

 

Cool Effect Announces Availability of Carbon Offset Guide as a Resource for Sustainable InitiativesOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Cool Effect, a Bay Area based non-profit focused on fighting the climate crisis, today announces the availability, on its website, of Securing Climate Benefit: A Guide to Using Carbon Offsets. The Stockholm Environment Institute (SEI) and Greenhouse Gas Management Institute (GHGMI), together with High Tide Foundation, developed the guide as an educational resource for businesses and individuals looking to reduce their impact by purchasing carbon offsets. The guid

 

Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)Open in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is announcing today a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic porphyria (AHP) – an ultra-rare orphan disease – gain access to GIVLAARI™ (givosiran) injection for subcutaneous use, a first-of-its-kind RNAi therapeutic for the treatment of AHP. Approved today by the U.S. Food and Drug Administration (FDA), GIVLAAR

 

Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)Open in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved GIVLAARI™ (givosiran) injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact da

 

New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery PatientsOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Clinical trial results confirming PleuraFlow enabling improved quality and cost for post cardiac surgery care have been published.

 

Boundless Bio Announces Publication in Nature Elucidating the Role of Extrachromosomal DNA (ecDNA) Structure in Cancer BiologyOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio announces publication in the journal Nature elucidating the role of extrachromosomal DNA (ecDNA) structure in cancer biology.

 

2019 Info-Tech CIO Awards Celebrate Outstanding IT Leaders Who Deliver Business ValueOpen in a New Window

LAS VEGAS--(BUSINESS WIRE)--Info-Tech Research Group today announced the 2019 Info-Tech CIO award winners at Info-Tech LIVE, being held in Las Vegas this week, Nov. 19-21. The most authoritative event for IT executives and leaders globally, the two days of Info-Tech LIVE will be filled with engaging and informative sessions led by Info-Tech’s research analysts and practitioners. At the event, Info-Tech will hold the 2019 Info-Tech CIO awards ceremony, honoring outstanding CIOs, based on unbiase

 

Invicro’s Software Leadership Team Expands with Two New ExecutivesOpen in a New Window

BOSTON--(BUSINESS WIRE)-- #biomarkers--Invicro LLC, a Konica Minolta Company, today announced the expansion of their Software leadership team with the hiring of Mr. Chris Fuller, Vice President of Software and Mr. Timothy Moran as Senior Director of Product Management. Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development. Backed by more than 20 years of software consulting and engineering management, Mr. Fuller wil

 

Fuse Medical Ranked Number 89 Fastest Growing Company in North America on Deloitte’s 2019 Technology Fast 500™Open in a New Window

RICHARDSON, Texas--(BUSINESS WIRE)--Fuse Medical, Inc., (OTCPK: FZMD), an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it ranked number 89 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 25th year. During the selected period Fuse’s revenue grew 1471%. Fuse Medical’s Chief Executive Offi

 

Genprex Announces $1.26 Million Registered Direct OfferingOpen in a New Window

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex announces a registered direct offering

 

Dermatology Times® Seeks Final Nominations for Giants of Dermatology 2020 Awards ProgramOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)-- #awardprogram--The window for nominations of the Giants of Dermatology program will officially be closed on Jan. 1, 2020.

 

Carbon Nanotube Technology Exceeds 100GHz for First Time in RF ApplicationsOpen in a New Window

CULVER CITY, Calif.--(BUSINESS WIRE)--Carbon nanotube technology exceeds 100GHz for first time in RF applications. Carbonics, Inc.’s technology eclipses incumbent RF CMOS technology.

 

Blink Health Welcomes Gene McKenna as Head of Performance Marketing & AnalyticsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Blink Health, the digital health company on a mission to make prescription drugs affordable for everyone, has appointed Gene McKenna as Head of Performance Marketing & Analytics. He joins the company with over 15 years of leadership experience managing global marketing, product and engineering teams. Most recently, McKenna served as VP & GM at Groupon, where he led strategy and oversaw approximately $1 billion in annual sales. “Gene’s impressive professional b

 

Data Show Zilver® PTX® Leads to Fewer Complications and Shorter Hospital Stays Than Traditional Bypass SurgeryOpen in a New Window

BLOOMINGTON, Ind.--(BUSINESS WIRE)--At this year’s VEITHsymposium®, Dr. Marc Bosiers presented data that show that patient treatment with the Zilver® PTX® stent has several benefits when compared to traditional bypass surgery. The data, which were gathered from a randomized controlled trial, show that treatment with Zilver PTX results in fewer complications and shorter hospital stays for patients with peripheral artery disease (PAD).1 PAD affects more than 236 million people worldwide.2 Zilver

 

SOPHiA GENETICS Welcomes Milton Silva-Craig to its Board of DirectorsOpen in a New Window

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS Welcomes Milton Silva-Craig to its Board of Directors.

 

RTI International Partners with North Carolina Department of Public Safety to Evaluate Effectiveness of Web-based Re-entry Planning Tool, Pokket℠Open in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--RTI International today announced a partnership with the North Carolina Department of Public Safety to test new web-based, re-entry tool Pokket.

 

TriSalus™ Life Sciences’ Surefire® Spark™ Infusion System (TriNav™) Receives CMS Approval for Transitional Pass-Through Payment StatusOpen in a New Window

DENVER--(BUSINESS WIRE)-- #HCC--TriSalus™ Life Sciences’ Surefire® Spark™ Infusion System (TriNav™) Receives CMS Approval for Transitional Pass-Through Payment Status

 

California Life Sciences Association (CLSA) Adds Leaders from AbbVie, Merck and Lasana Partners to Board of DirectorsOpen in a New Window

SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)-- #Abbvie--California Life Sciences Association (CLSA) Adds Leaders from AbbVie, Merck and Lasana Partners to Board of Directors

 

BioTeam Promotes Industry Veteran Dr. Ari Berman to CEOOpen in a New Window

MIDDLETON, Mass.--(BUSINESS WIRE)--BioTeam Names New CEO

 

Dr. Suzie Bash Joins CorTechs Labs Medical Advisory BoardOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--CorTechs Labs Inc. is pleased to announce that Dr. Suzie Bash, one of the most highly regarded neuroradiologists in the United States (U.S.), has joined the company’s medical advisory board and will bring significant clinical expertise. Dr. Bash has been an expert user of CorTechs Labs’ volumetric magnetic resonance imaging (MRI) solution, NeuroQuant®, for over 12 years and is an avid supporter of the technology, contributing, as a user, to its development. This form

 

PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal ImmunonutritionOpen in a New Window

BOULDER, Colo.--(BUSINESS WIRE)--PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies, today announced a multimillion dollar agreement between its wholly-owned subsidiary APS BioGroup and VitaDairy, the leading Vietnamese nutritional dairy company. The signing of the agreement marks a pivotal moment for VitaDairy, the Growing-Up Milk market, and the health of children in Vietnam. Under the three-year deal, APS BioGroup has become VitaDairy’

 

Tandem Diabetes Care Announces Health Canada Approval of t:slim X2 Insulin Pump with Basal-IQ Predictive Low-Glucose Suspend TechnologyOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care announces Health Canada approval of t:slim X2 insulin pump with Basal-IQ predictive low-glucose suspend technology

 

MathWorks Boosts Support for Scientific Research with Updated Access Model for MATLAB and MATLAB Parallel ServerOpen in a New Window

NATICK, Mass.--(BUSINESS WIRE)--MathWorks expands access to MATLAB and MATLAB Parallel Server to accelerate scientific research and enable collaboration.

 

Independent Health announces new Medicare Advantage transportation benefit in partnership with SafeRide HealthOpen in a New Window

BUFFALO, N.Y.--(BUSINESS WIRE)-- #medicare--Independent Health announces a new Medicare Advantage transportation benefit for 2020 through a strategic partnership with SafeRide Health, a non-emergency medical transportation technology and services leader dedicated to driving healthier lives. Through this new collaboration, Independent Health is leading the way in Western New York offering an innovative, technology-forward benefit for Medicare enrollees looking for plans that make quality healthcare easier t

 

SingleCare Prescription Savings Service Rolls out Drug Basket for Shopping Lowest Prices on Multiple MedicationsOpen in a New Window

BOSTON--(BUSINESS WIRE)--SingleCare®, the free prescription savings service, today announced it has launched a new feature, “Drug Basket,” enabling consumers to conveniently and efficiently access the lowest consolidated prices for all their prescription drugs at nearby pharmacies. According to research from the Mayo Clinic, more than half of Americans are on two prescription medications and 20 percent take five or more. SingleCare’s Drug Basket is a time and money saving solution for consumers

 

Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available OnlineOpen in a New Window

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology. This data can now be accessed on the compan

 

BTIG Announces Expansion of Equity Research Division with Consumer Lifestyle and Wellness Brands Analyst Camilo LyonOpen in a New Window

NEW YORK--(BUSINESS WIRE)--BTIG announced today that Camilo Lyon has joined the firm’s Research and Strategy division to launch coverage across the consumer sector, focusing on lifestyle and wellness brands. He will be based in the firm’s New York office, and will report to David Lenchus, Director of Research at BTIG. Mr. Lyon has more than 20 years of industry experience. He has spent the majority of his career covering the consumer sector inclusive of multi-national retail brands and emerging

 

New Carestream Digital Imaging Offerings Receive FDA ClearanceOpen in a New Window

ROCHESTER, N.Y.--(BUSINESS WIRE)-- #RSNA--Carestream's Dual-Energy imaging technology and Focus 35C Detector with Image Suite Software receive FDA Clearance, will be showcased at RSNA 2019.

 

Hope Biosciences Receives FDA Approval to Commence Groundbreaking Stem Cell Clinical Trial for Alzheimer’s DiseaseOpen in a New Window

HOUSTON--(BUSINESS WIRE)--Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimer’s Disease, in partnership with Altoida, Inc., a predictive digital biomarker company. “This study will utilize our proprietary core technology t

 

HDR InfiniBand Selected by Meteo France to Accelerate Two New Large Scale SupercomputersOpen in a New Window

DENVER--(BUSINESS WIRE)-- #Mellanox--SUPERCOMPUTING CONFERENCE – Mellanox® Technologies, Ltd. (NASDAQ: MLNX), a leading supplier of high-performance, end-to-end smart interconnect solutions for data center servers and storage systems, today announced that HDR InfiniBand has been selected by Meteo France to accelerate two new large-scale supercomputers, based on Atos’s latest BullSequana XH2000 technology. HDR InfiniBand ConnectX®-6 adapters, Mellanox Quantum™ switches and LinkX cables and transceivers will

 

Twist Bioscience to Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on Wednesday, December 11, 2019Open in a New Window

SAN FRANCISCO--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2019, following the close of market on Wednesday, December 11, 2019. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Tim

 

Kronos Bio Appoints Biopharma Industry Veteran Jorge F. DiMartino, M.D., Ph.D., as Chief Medical OfficerOpen in a New Window

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., dedicated to the development of first-in-class therapies that modulate historically undruggable targets, announced today that it has appointed Jorge F. DiMartino, M.D., Ph.D., as Chief Medical Officer and Executive Vice President, Clinical Development. In this newly created position, Dr. DiMartino will lead Kronos Bio’s clinical function and oversee the advancement of its oncology pipeline, which includes two preclinical p

 

Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of DirectorsOpen in a New Window

BOSTON--(BUSINESS WIRE)--Cardurion Pharmaceuticals announced a private investment from Polaris Partners to enable development of therapeutics for cardiovascular diseases.

 

Twist Bioscience Promotes Patrick J. Finn, Ph.D., to Chief Commercial OfficerOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick J. Finn, Ph.D., to the newly-created position of chief commercial officer. Dr. Finn previously served as senior vice president of commercial operations. “Paddy built our global sales, marketing and support organizations from the ground up, led the

 

Massive Bio and The American Sexual Health Association Partner to Increase Patient Access to Cervical Cancer Clinical TrialsOpen in a New Window

NEW YORK--(BUSINESS WIRE)-- #ChildhoodCancerAwareness--Massive Bio and The American Sexual Health Association Partner to Increase Patient Access to Cervical Cancer Clinical Trials

 

Soleo Health Acquires Paragon Infusion Therapy, a Midwest Regional Specialty Infusion ProviderOpen in a New Window

McKINNEY, Texas--(BUSINESS WIRE)-- #SoleoHealthRanks6thDBJlist--SOLEO HEALTH ACQUIRES PARAGON INFUSION THERAPY, A MIDWEST REGIONAL SPECIALTY INFUSION PROVIDER

 

Axcella Announces Issuance of Broad Patent Covering EMM CompositionsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella's third patent covers composition and method of use for NASH candidates and other EMMs.

 

New Dentsply Sirona website expands world-class education offeringsOpen in a New Window

CHARLOTTE, N.C.--(BUSINESS WIRE)--The Dentsply Sirona Academy provides the clinical and technical knowledge, skills and inspiration that dental professionals need to develop themselves and their practices. This education encompasses more than 11,000 courses, meetings and events, 42 Education Centers including those in Charlotte, North Carolina and Bensheim, Germany, and now an expanded online presence on www.dentsplysirona.com. The “learn” section of the new state-of-the art online platform for

 

ReForm Biologics Announces Issuance of U.S. Patent on Additional Excipients for Therapeutic Protein FormulationsOpen in a New Window

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 10,478,498 (the ‘498 patent). This patent, entitled “Excipient Compounds for Biopolymer Formulations,” provides ReForm exclusive rights to certain formulations containing combinations of its proprietary excipients that significantly enhance the viscosity reduction of the highly c

 

Hologic to Sell Cynosure Medical Aesthetics Business to Clayton, Dubilier & RiceOpen in a New Window

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic to Sell Cynosure Medical Aesthetics Business to Clayton, Dubilier & Rice

 

Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-OncologyOpen in a New Window

ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced 43 presentations on Tumor Treating Fields will be presented at the 24th Annual Meeting of the Society for Neuro-Oncology.

 

WithMe Health Continues Rapid Growth with Expansion of Leadership TeamOpen in a New Window

SAN MATEO, Calif.--(BUSINESS WIRE)--WithMe Health, the Personalized Medication Guidance company, has welcomed four new executives to its team.

 

InformedDNA Unveils Unique Approach to Genetic Test Policy DevelopmentOpen in a New Window

ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- #geneticcounseling--InformedDNA®, the nation's largest independent provider of genetics services, today released details of its Coverage Decision Framework™ which enables health plans to offer members improved access to emerging genetic tests. This innovative approach is described in the latest issue of the company’s original research and analysis series, Informed Insights™, which explores trends and strategies to address barriers as advances in genomics continue to reshape t

 

Castle Biosciences to Present at Upcoming Investor ConferencesOpen in a New Window

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences will present at upcoming investor conferences.

 

Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%Open in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol-Myers Squibb Announces Topline Results for Opdivo Plus Yervoy Versus Opdivo Alone in Resected High-Risk Melanoma Patients

 

Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare ConferenceOpen in a New Window

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference as follows:   Date: Tuesday, December 3, 2019 Time: 11:30 a.m. Eastern Standard Time Location: Lotte New York Palace, New York, NY Webcast: https://event.webcasts.com/starthere.jsp?ei=1273124&tp_key=d0b36ea10f The p

 

European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Open in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves Two New Regimens of Merck’s KEYTRUDA as First-Line Treatment for Metastatic or Unresectable Recurrent HNSCC

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect